LILRB2 NFAT Luciferase Reporter Jurkat Cell Line

LILRB2 NFAT Luciferase Reporter Jurkat Cell Line is a Jurkat cell line that expresses human LILRB2 (leukocyte immunoglobulin-like receptor subfamily B member 2) and the firefly luciferase reporter under the control of NFAT response elements located upstream of the minimal TATA promoter. LILRB2 expression was verified by flow cytometry, and this cell line was functionally validated with anti-LILRB2 and anti-HLA-G1 neutralizing antibodies in co-culture assays. LILRB2 (leukocyte immunoglobulin-like receptor subfamily B member 2), also known as ILT4, LIR2 or CD85D, is one of the 13 members of the LILR family of proteins characterized by associating with membrane adaptor proteins to trigger signals via ITIMS (immunoreceptor tyrosine-based inhibitory motifs) present in their long cytoplasmic tail. It is located on human chromosome 19q13.4, in the leukocyte receptor complex region, with other innate immune families of the Ig superfamily. It acts as an inhibitory receptor. It is expressed in monocytes, macrophages, and DCs (dendritic cells), and plays roles in synaptic plasticity, neurite growth and activation, and differentiation of immune cells. It has been shown to interact strongly with Amyloid beta oligomers and has been implicated in AD (Alzheimer's disease), with anti-LILRB2 blocking antibodies showing promise in promoting microglia functions. It is found in the microenvironment of many types of tumors where it contributes to immune escape. Targeting LILRB2 is an active focus in antibody clinical research and may benefit patients suffering from LILRB2- related disorders.